HXN-1001
/ Earendil Labs
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 10, 2025
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
(The Manila Times)
- "Earendil Labs...announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibody (HXN-1001). The phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HXN-1001 in healthy volunteers."
New P1 trial • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1